Blueprint Medicines Corporation (BPMC) — Financial statements
Income statement, balance sheet, and cash flow for Blueprint Medicines Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 509↑104.0% | 249↑22.2% | 204↑13.3% | 180↓77.3% | 794 | |
| Cost of Revenue | 20↑57.6% | 13↓28.2% | 18↓0.7% | 18↑4119.8% | 0.43 | |
| Gross Profit | 489↑106.5% | 237↑27.0% | 186↑14.8% | 162↓79.6% | 793 | |
| Operating Expenses | ||||||
| R&D Expenses | 341↓20.2% | 428↓10.4% | 477↓20.6% | 601↑83.9% | 327 | |
| General & Administrative Expenses | 263↓5.6% | 278↑26.9% | 219↑20.6% | 182↑22.5% | 148 | |
| Selling & Marketing Expenses | 97↑471.6% | 17↓6.6% | 18↑34.1% | 14↑43.6% | 9 | |
| SG&A Expenses | 359↑21.7% | 295↑24.3% | 237↑21.5% | 195↑23.8% | 158 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 9↑14.7% | 8↑2231.4% | -0.37 | |
| Operating Expenses | 701↓3.1% | 723↓0.1% | 724↓10.0% | 804↑65.9% | 485 | |
| Total Costs & Expenses | 721↓2.0% | 736↓0.8% | 742↓9.8% | 822↑69.5% | 485 | |
| Operating Results | ||||||
| Operating Income | -212↑56.4% | -486↑11.5% | -549↑15.3% | -648↓314.6% | 302 | |
| Depreciation & Amortization | 16↑39.7% | 12↓42.0% | 20↑57.2% | 13↑3.5% | 12 | |
| EBITDA | 19↑104.1% | -470↑8.7% | -515↑18.0% | -628↓303.5% | 309 | |
| EBIT | 3↑100.6% | -482↑8.8% | -529↑17.6% | -641↓303.6% | 315 | |
| Interest & Other Income | ||||||
| Net Interest Income | -28↓49.8% | -19↓12.1% | -17↓802.7% | 2↓63.8% | 7 | |
| Interest Income | 41↑23.9% | 33 | 0.00↓100.0% | 2↓63.8% | 7 | |
| Interest Expense | 69↑33.3% | 52↑207.8% | 17 | 0.00 | 0.00 | |
| Non-Operating Income | -215↓4951.4% | -4↑52.4% | -9↓897.5% | -0.90↑85.6% | -6 | |
| Other Income / Expenses | 146↑840.6% | -20↓33.7% | -15↓1745.8% | 0.90↓85.6% | 6 | |
| Income Before Tax | -66↑87.0% | -506↑8.4% | -552↑13.9% | -641↓303.6% | 315 | |
| Income Tax Expense | 1↑26.7% | 0.97↓81.5% | 5↑74.5% | 3↑183.6% | 1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -67↑86.8% | -507↑9.1% | -558↑13.4% | -644↓305.2% | 314 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -67↑86.8% | -507↑9.1% | -558↑13.4% | -644↓305.2% | 314 | |
| Bottom-Line Net Income | -67↑86.8% | -507↑9.1% | -558↑13.4% | -644↓305.2% | 314 | |
| EPS (Basic) | -1.07↑87.2% | -8.37↑10.5% | -9.35↑15.1% | -11.01↓291.1% | 5.76 | |
| EPS (Diluted) | -1.07↑87.2% | -8.37↑10.5% | -9.35↑15.1% | -11.01↓297.0% | 5.59 | |
| Weighted Average Shares | 63↑3.8% | 61↑1.5% | 60↑1.9% | 59↑7.3% | 55 | |
| Weighted Average Diluted Shares | 63↑3.8% | 61↑1.5% | 60↑1.9% | 59↑4.2% | 56 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.